CohBar Announces the Appointment of Dr. Phyllis Gardner to its Board of Directors
February 11, 2019 09:00 ET
|
CohBar, Inc.
MENLO PARK, Calif., Feb. 11, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related...
CohBar Appoints Philippe P. Calais, Pharm.D., Ph.D. as Interim Chief Executive Officer
December 10, 2018 16:05 ET
|
CohBar, Inc.
MENLO PARK, Calif., Dec. 10, 2018 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related...
CohBar Founder Dr. Nir Barzilai Awarded the 2018 Fondation IPSEN Longevity Prize
November 26, 2018 09:00 ET
|
CohBar, Inc.
MENLO PARK, Calif., Nov. 26, 2018 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related...
CohBar Reports Third Quarter 2018 Financial Results and Provides Business Update
November 14, 2018 16:03 ET
|
CohBar, Inc.
Will Host Conference Call on November 14, 2018 at 5:00 p.m. Eastern Time MENLO PARK, Calif., Nov. 14, 2018 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company...
CohBar Co-Founder and Scientific Advisor Dr. David Sinclair Named as one of TIME Magazine’s Health Care 50
November 08, 2018 09:00 ET
|
CohBar, Inc.
Cited for his groundbreaking work on the underlying metabolic causes of aging MENLO PARK, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology...
CohBar Provides Update on CB4211 Clinical Trial
November 05, 2018 09:00 ET
|
CohBar, Inc.
CB4211 Phase 1 Clinical Trial Temporarily Suspended to Address Injection Site Reactions Will Host Conference Call on November 6, 2018 at 11:00 a.m. Eastern Time MENLO PARK, Calif., Nov. 05, 2018 ...
CohBar to Announce 2018 Third Quarter Financial Results and Host Conference Call on November 14, 2018
October 31, 2018 09:00 ET
|
CohBar, Inc.
MENLO PARK, Calif., Oct. 31, 2018 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related...
CohBar Engages LifeSci Advisors as Investor Relations Partner
September 25, 2018 09:00 ET
|
CohBar, Inc.
MENLO PARK, Calif., Sept. 25, 2018 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related...
CohBar Announces Second Quarter 2018 Financial Results
August 14, 2018 16:03 ET
|
CohBar, Inc.
MENLO PARK, Calif., Aug. 14, 2018 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related...
CohBar, Inc. to Announce 2018 Second Quarter Financial Results and Host Conference Call for Shareholders on August 14, 2018
August 02, 2018 13:09 ET
|
CohBar, Inc.
MENLO PARK, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related...